Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial (pages 1908–1915)
Howard A. Burris III, Fabienne Lebrun, Hope S. Rugo, J. Thaddeus Beck, Martine Piccart, Patrick Neven, Jose Baselga, Katarina Petrakova, Gabriel N. Hortobagyi, Anna Komorowski, Edmond Chouinard, Robyn Young, Michael Gnant, Kathleen I. Pritchard, Lee Bennett, Jean-Francois Ricci, Hounayda Bauly, Tetiana Taran, Tarek Sahmoud and Shinzaburo Noguchi
Version of Record online: 15 MAR 2013 | DOI: 10.1002/cncr.28010
In the randomized, controlled BOLERO-2 (Breast Cancer Trials of Oral Everolimus) trial, postmenopausal women with hormone receptor-positive advanced breast cancer who developed disease progression while receiving letrozole or anastrozole and who then received treatment with everolimus plus exemestane (EVE + EXE) experienced a longer time to definitive deterioration in global health-related quality of life (HRQOL) than those treated with placebo and EXE. Combined with significant improvements in clinical efficacy, these HRQOL findings provide added support for the benefit of EVE + EXE in this patient population.